
    
      Participants will receive a 2-hour intravenous infusion of study drug (tasisulam) once every
      28 days. Radiological imaging scans will be performed before the first dose of study drug and
      then after every other treatment. Participants will be assessed for clinical progression at
      every visit and for response approximately every 56 days (every other cycle).
    
  